Acta Scientific Ophthalmology (ISSN: 2582-3191)

Case Report Volume 3 Issue 10

Synergistic Effect of Concurrent Radiotherapy with Adjuvant Vismodegib on Aggressive Intracranial and Orbital Invasion with Basal Cell Carcinoma of Scalp

Bahram Eshraghi and Babak Masoomian*

Oculoplastic and Ocular Oncology Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran

*Corresponding Author: Babak Masoomian, Oculoplastic and Ocular Oncology Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Received: September 09, 2020; Published: October 07, 2020

×

Abstract

  The purpose of this study is to report a case with visual loss eye secondary to intracranial and orbital spreading of scalp Basal cell carcinoma (BCC) in which provided amazing response to combination of radiotherapy and oral Vismodegib. A 69-years-old man 3 years after invasive scalp BCC excisional biopsy and radiotherapy presented with a gradual decrease in his vision, proptosis and limited ocular motilities in his left eye. Magnetic resonance imaging revealed 360 encircle thickening with soft tissue enhancement around left orbital apex and whole cavity. Orbital biopsy showed subperiostal extension of BCC that was extended to frontal bone. Two weeks after surgery the patient’s left eye vision dropped quickly to the level of light perception. He underwent stereotactic radiotherapy adjuvant with 150 mg daily oral Vismodegib at the same time. Due to gastrointestinal problems, the patient refused to take vismodegib beyond 2 months. One year later, despite incomplete treatment, the vision of left eye was 20/200 and no recurrence was detected clinically or by imaging.

Keywords: Basal Cell Carcinoma; Intracranial Invasion; Radiotherapy; Vismodegib

×

References

  1. Gandhi SA and Kampp J. "Skin Cancer Epidemiology, Detection, and Management". The Medical Clinics of North America6 (2015): 1323-1335.
  2. Walling HW., et al. “Aggressive basal cell carcinoma: presentation, pathogenesis, and management”. Cancer and Metastasis Reviews 3-4 (2004): 389-402.
  3. Lo JS., et al. “Metastatic basal cell carcinoma: report of twelve cases with a review of the literature”. Journal of the American Academy of Dermatology 24 (1991): 715-719.
  4. Franco AI., et al. “Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma”. Case Reports in Dermatological Medicine (2018): 2354146.
  5. Sims-Mourtada J., et al. “Hedgehog: an attribute to tumor re growth after chemoradiotherapy and a target to improve radiation response”. Clinical Cancer Research 21 (2006): 6565-6572.
  6. Eiger-Moscovich M., et al. “Efficacy of Vismodegib for the Treatment of Orbital and Advanced Periocular Basal Cell Carcinoma”. American Journal of Ophthalmology (2019).
  7. Irish JC., et al. “Tumors of the Skull base: outcome and survival analysis of 77 cases”. Head Neck 16 (1994): 3-10.
  8. Parizel PM., et al. “Deep cerebral invasion by basal cell carcinoma of the scalp”. Neuroradiology 38 (1996): 575-579.
  9. Long SD., et al. “Intracranial extension of basal cell carcinoma of the scalp”. Computerized Medical Imaging and Graphics 17 (1993): 469-471.
  10. Kovarik CL., et al. “Lethal basal cell carcinoma secondary to cerebral invasion”. Journal of the American Academy of Dermatology 52 (2005): 149-151.
  11. Olschewski T., et al. “[Radiotherapy of basal cell carcinoma of the face and head: Importance of low dose per fraction on long-term outcome]”. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2 (2006): 124-130.
  12. Kwon CS., et al. “Basal cell carcinoma of the scalp with destruction and invasion into the calvarium and dura mater: Report of 7 cases and review of literature”. Journal of Clinical Neuroscience 47 (2018): 190-197.
×

Citation

Citation: Bahram Eshraghi and Babak Masoomian. “Synergistic Effect of Concurrent Radiotherapy with Adjuvant Vismodegib on Aggressive Intracranial and Orbital Invasion with Basal Cell Carcinoma of Scalp". Acta Scientific Paediatrics 3.11 (2020): 04-07.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
ISI- IF1.042
JCR- IF0.24

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 15, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US